Dr. The disease. Presented preliminary data from the Phase 1b study in Novel Therapeutics and Drug Resistance session in an oral presentation entitled ‘# 1070: PX-171-006: Phase IB Multicenter Dose Escalation Study of Carfilzomib and lenalidomide and Low Dose dexamethasone in relapsed and refractory multiple myeloma . Preliminary Results ‘.
The median time to disease progression in this cohort was 8.9 months. Ten other patients achieved stable disease. – Carfilzomib monotherapy achieves durable responses in relapsed multiple myeloma patients , regardless of their previous exposure to bortezomib and in particular a series of patients without progression after twelve cycles remain, said Dr. Stewart. In addition, carfilzomib was generally well tolerated, and the connection of selectivity seems the off-target effects, ,, can be avoided with the currently available proteasome inhibitors. .. In patients with prior bortezomib exposure, 18 % achieved partial response and the median duration of response in this population.But while these platforms to shows us what does not to a circuit, show it us how it works.
Written David Cameron ‘Network Anatomie and in vivo physiology of out of a group of visual cortical neurons ‘ – 1 Davi D. Bock , the other male , Greg Hood , Arthur W. Wetzel , Sergey Yurgenson , Edward R. Soucy , Hyon Suk Kim .
Researchers at the Harvard Medical School Department of Neurobiology have developed a technique for deciphering the mass. Using a combination of microscopy platforms , researchers crawling crawl about the individual connections composing one neural network as Google crawls web links. – The questions which one such technique allows we are address too numerous too numerous even to overview, said Clay Reid, HMS Professor for Neurobiology and senior author of at a paper reporting the results at the 10th March edition out of Nature.